Erik W Bloomquist
Overview
Explore the profile of Erik W Bloomquist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maguire W, Lee D, Weinstock C, Gao X, Bulik C, Agrawal S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2011-2016.
PMID: 38441576
On April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (EV) plus pembrolizumab for treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for...
2.
Gao J, Osgood C, Feng Z, Bloomquist E, Tang S, Chang C, et al.
Clin Cancer Res
. 2023 Aug;
29(24):5008-5011.
PMID: 37594723
On December 10, 2021, the FDA expanded the indications for ribociclib to include male patients for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Ribociclib is now...
3.
Vellanki P, Ghosh S, Pathak A, Fusco M, Bloomquist E, Tang S, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36796877
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as...
4.
Fallah J, Brave M, Weinstock C, Mehta G, Bradford D, Gittleman H, et al.
Clin Cancer Res
. 2022 Jun;
28(22):4843-4848.
PMID: 35727604
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal...
5.
Arora S, Narayan P, Osgood C, Wedam S, Prowell T, Gao J, et al.
Clin Cancer Res
. 2021 Oct;
28(6):1072-1086.
PMID: 34711632
Over the last decade, the treatment of patients with breast cancer has been greatly impacted by the approval of multiple drugs and indications. This summary describes 30 FDA approvals of...
6.
Arora S, Narayan P, Ison G, Berman T, Suzman D, Wedam S, et al.
Clin Cancer Res
. 2021 Oct;
28(6):1058-1071.
PMID: 34711631
Over the last decade, there has been tremendous progress in the treatment of patients with gynecologic cancers with a changing therapy landscape. This summary provides an overview of U.S. Food...
7.
Amatya A, Fiero M, Bloomquist E, Sinha A, Lemery S, Singh H, et al.
Clin Cancer Res
. 2021 Jun;
27(21):5753-5756.
PMID: 34117032
Subgroup analyses are assessments of treatment effects based on certain patient characteristics out of the total study population and are important for interpretation of pivotal oncology trials. However, appropriate use...
8.
Gao J, Osgood C, Gong Y, Zhang H, Bloomquist E, Jiang X, et al.
Clin Cancer Res
. 2020 Nov;
27(8):2126-2129.
PMID: 33188141
On June 29, 2020, the FDA approved pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection (Phesgo) for the treatment of patients with HER2-positive early-stage and metastatic breast cancer. Patients should be selected...
9.
Brewer J, Chang E, Agrawal S, Singh H, Suzman D, Xu J, et al.
Clin Cancer Res
. 2020 Aug;
26(24):6406-6411.
PMID: 32732222
The development and review of combination drug regimens in oncology may present unique challenges to investigators and regulators. For regulatory approval of combination regimens, it is necessary to demonstrate the...
10.
Kubatko L, Gibbs H, Bloomquist E
Syst Biol
. 2011 Mar;
60(4):393-409.
PMID: 21389297
Phylogenetic relationships and taxonomic distinctiveness of closely related species and subspecies are most accurately inferred from data derived from multiple independent loci. Here, we apply several approaches for understanding species-level...